{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:24:53Z","timestamp":1789752293440,"version":"4.0.1"},"reference-count":232,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.critrevonc.2015.11.004","type":"journal-article","created":{"date-parts":[[2015,11,28]],"date-time":"2015-11-28T19:35:02Z","timestamp":1448739302000},"page":"375-389","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Myeloproliferative neoplasms: Current molecular biology and genetics"],"prefix":"10.1016","volume":"98","author":[{"given":"Kolsoum","family":"Saeidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2015.11.004_bib0005","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.3324\/haematol.13187","article-title":"Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias","volume":"93","author":"Abbas","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0010","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2009-11-250878","article-title":"Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value","volume":"116","author":"Abbas","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0015","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood-2009-03-210039","article-title":"Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies","volume":"114","author":"Abdel-Wahab","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0020","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/0008-5472.CAN-09-3783","article-title":"Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias","volume":"70","author":"Abdel-Wahab","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0025","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/leu.2011.82","article-title":"DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms","volume":"25","author":"Abdel-Wahab","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0030","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccr.2012.06.032","article-title":"ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression","volume":"22","author":"Abdel-Wahab","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0035","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/sj.leu.2402554","article-title":"A novel MPL point mutation resulting in thrombopoietin-independent activation","volume":"16","author":"Abe","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0040","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4274\/tjh.65807","article-title":"MPL W515L\/K Mutations in chronic myeloproliferative neoplasms","volume":"30","author":"Akpinar","year":"2013","journal-title":"Turk. J. Haematol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0045","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cancergencyto.2007.05.009","article-title":"HMGA2 overexpression in polycythemia vera with t(12;21)(q14;q22)","volume":"177","author":"Aliano","year":"2007","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0050","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1309\/AJCPEI9XU8PYBCIO","article-title":"FLT3 and NPM1 mutations in myelodysplastic syndromes: frequency and potential value for predicting progression to acute myeloid leukemia","volume":"135","author":"Bains","year":"2011","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0055","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood-2009-02-206797","article-title":"Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?","volume":"114","author":"Barbui","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0060","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0065","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0070","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1182\/blood-2007-07-099184","article-title":"JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis","volume":"110","author":"Barosi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0075","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.beha.2014.07.004","article-title":"Essential thrombocythemia vs. early\/prefibrotic myelofibrosis: why does it matter","volume":"27","author":"Barosi","year":"2014","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0080","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1136\/jclinpath-2011-200175","article-title":"Epigenomic profiling in polycythaemia vera and essential thrombocythaemia shows low levels of aberrant DNA methylation","volume":"64","author":"Barrio","year":"2011","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0085","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0090","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","article-title":"MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort","volume":"112","author":"Beer","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0095","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2009-08-236596","article-title":"Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm","volume":"115","author":"Beer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0100","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.3324\/haematol.2010.029306","article-title":"Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms","volume":"95","author":"Beer","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0105","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1182\/blood-2002-04-1204","article-title":"Signal transducer and activator of transcription proteins in leukemias","volume":"101","author":"Benekli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0110","first-page":"2832","article-title":"Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2","volume":"118","author":"Bersenev","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0115","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1365-2141.2010.08083.x","article-title":"Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis","volume":"149","author":"Boyd","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0120","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1038\/bcj.2011.15","article-title":"Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes","volume":"1","author":"Brecqueville","year":"2011","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0125","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/gcc.21960","article-title":"Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms","volume":"51","author":"Brecqueville","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0130","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1182\/blood-2014-06-583161","article-title":"Presence of calreticulin mutations in JAK2-negative polycythemia vera","volume":"124","author":"Broseus","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0135","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/sj.leu.2404971","article-title":"Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients","volume":"22","author":"Butcher","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0140","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2006-12-061176","article-title":"Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia","volume":"110","author":"Caligiuri","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0145","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0150","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood-2005-08-3395","article-title":"V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis","volume":"107","author":"Campbell","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0155","doi-asserted-by":"crossref","first-page":"150","DOI":"10.5581\/1516-8484.20120035","article-title":"Molecular biology of Philadelphia-negative myeloproliferative neoplasms","volume":"34","author":"Campregher","year":"2012","journal-title":"Rev. Bras. Hematol. Hemoterapia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0160","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1365-2141.2008.07072.x","article-title":"Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders","volume":"141","author":"Capello","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0165","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/leu.2009.141","article-title":"Mutations of ASXL1 gene in myeloproliferative neoplasms","volume":"23","author":"Carbuccia","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0170","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/leu.2009.218","article-title":"Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias","volume":"24","author":"Carbuccia","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0175","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2006-09-046342","article-title":"Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status","volume":"109","author":"Carobbio","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0180","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1200\/JCO.2007.15.3569","article-title":"Leukocytosis and risk stratification assessment in essential thrombocythemia","volume":"26","author":"Carobbio","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0185","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1182\/blood-2014-03-530865","article-title":"From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms","volume":"123","author":"Cazzola","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0190","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0195","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/leu.2008.137","article-title":"New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1\/S-phase transition","volume":"22","author":"Chaligne","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0200","article-title":"Acquired somatic mutations of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in preleukemic disorders","author":"Chotirat","year":"2014","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0205","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/jcb.23089","article-title":"The thrombopoietin\/MPL pathway in hematopoiesis and leukemogenesis","volume":"112","author":"Chou","year":"2011","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0210","doi-asserted-by":"crossref","first-page":"401","DOI":"10.5581\/1516-8484.20110110","article-title":"The importance of cytogenetics in polycythemia vera, primary myelofibrosis and essential thrombocythemia","volume":"33","author":"Conchon","year":"2011","journal-title":"Rev. Bras. Hematol. Hemoterapia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0215","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.molmed.2010.07.002","article-title":"IDH mutations in glioma and acute myeloid leukemia","volume":"16","author":"Dang","year":"2010","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0220","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0225","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1182\/blood-2003-10-3471","article-title":"Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin","volume":"103","author":"Ding","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0230","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1182\/blood-2009-06-223982","article-title":"AML1\/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms","volume":"114","author":"Ding","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0235","doi-asserted-by":"crossref","first-page":"417","DOI":"10.5581\/1516-8484.20110116","article-title":"Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia","volume":"33","author":"Dos Santos","year":"2011","journal-title":"Rev. Bras. Hematol. Hemoterapia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0240","doi-asserted-by":"crossref","first-page":"10349","DOI":"10.1158\/0008-5472.CAN-08-2754","article-title":"250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies","volume":"68","author":"Dunbar","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0245","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0250","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cancergencyto.2007.03.009","article-title":"Rearrangements involving 12q in myeloproliferative disorders: possible role of HMGA2 and SOCS2 genes","volume":"176","author":"Etienne","year":"2007","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0255","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0260","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.10634","article-title":"Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status","volume":"92","author":"Finazzi","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0265","first-page":"1329","article-title":"tyk2, prototype of a novel class of non-receptor tyrosine kinase genes","volume":"5","author":"Firmbach-Kraft","year":"1990","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0270","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.3324\/haematol.13043","article-title":"Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders","volume":"93","author":"Fourouclas","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0275","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/gcc.10204","article-title":"Identification of CBL, a proto-oncogene at 11q23.3, as a novel MLL fusion partner in a patient with de novo acute myeloid leukemia","volume":"37","author":"Fu","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0280","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nrc2271","article-title":"Roles of HMGA proteins in cancer","volume":"7","author":"Fusco","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0285","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/sj.leu.2404500","article-title":"Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients","volume":"21","author":"Gangat","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0290","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0295","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1365-2141.2009.07697.x","article-title":"Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia","volume":"145","author":"Gelsi-Boyer","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0300","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1756-8722-5-12","article-title":"Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases","volume":"5","author":"Gelsi-Boyer","year":"2012","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0305","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1365-2141.2006.06171.x","article-title":"Serial determination of FLT3 mutations in myelodysplastic syndrome patients at diagnosis, follow up or acute myeloid leukaemia transformation: incidence and their prognostic significance","volume":"134","author":"Georgiou","year":"2006","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0310","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri747","article-title":"Haematopoietic cell-fate decisions chromatin regulation and ikaros","volume":"2","author":"Georgopoulos","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0315","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1189\/jlb.0908575","article-title":"Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F","volume":"85","author":"Gery","year":"2009","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0320","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0325","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1182\/blood-2008-12-194548","article-title":"Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms","volume":"113","author":"Grand","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0330","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2007.06565.x","article-title":"Anaemia characterises patients with myelofibrosis harbouring Mpl mutation","volume":"137","author":"Guglielmelli","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0335","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","article-title":"EZH2 mutational status predicts poor survival in myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0340","doi-asserted-by":"crossref","first-page":"5292","DOI":"10.1073\/pnas.92.12.5292","article-title":"Distinct regions of c-Mpl cytoplasmic domain are coupled to the JAK-STAT signal transduction pathway and Shc phosphorylation","volume":"92","author":"Gurney","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0345","first-page":"173","article-title":"Analysis of the ten-eleven translocation 2 (TET2) gene mutation in myeloproliferative neoplasms","volume":"44","author":"Ha","year":"2014","journal-title":"Ann. Clin. Lab. Sci."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0350","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2003-09-3074","article-title":"High incidence of somatic mutations in the AML1\/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia","volume":"103","author":"Harada","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0355","article-title":"Dysregulation of the MIRLET7\/HMGA2 axis with methylation of the CDKN2A promoter in myeloproliferative neoplasms","author":"Harada-Shirado","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0360","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJMc1012718","article-title":"p53 lesions in leukemic transformation","volume":"364","author":"Harutyunyan","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0365","series-title":"Interferon\u2014 A Therapy and Clonal Architecture","article-title":"JAK2V617F-positive myeloproliferative neoplasms: KI mouse models","author":"Hasan","year":"2013"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0370","article-title":"Incidence of CALR mutations in patients with splanchnic vein thrombosis","author":"Haslam","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0375","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/leu.2008.371","article-title":"MPLW515L mutation in acute megakaryoblastic leukaemia","volume":"23","author":"Hussein","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0380","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1600-0609.2009.01224.x","article-title":"Conventional cytogenetics in myelofibrosis: literature review and discussion","volume":"82","author":"Hussein","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0385","doi-asserted-by":"crossref","first-page":"5860","DOI":"10.1182\/blood-2011-02-334425","article-title":"3'UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice","volume":"117","author":"Ikeda","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0390","doi-asserted-by":"crossref","first-page":"91","DOI":"10.5387\/fms.58.91","article-title":"The role of HMGA2 in the proliferation and expansion of a hematopoietic cell in myeloproliferative neoplasms","volume":"58","author":"Ikeda","year":"2012","journal-title":"Fukushima J. Med. Sci."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0395","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/leu.2014.124","article-title":"DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies","volume":"28","author":"Im","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0400","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/nature09303","article-title":"Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification","volume":"466","author":"Ito","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0405","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2174\/156800911793743628","article-title":"Molecular pathogenesis of Philadelphia chromosome negative chronic myeloproliferative neoplasms","volume":"11","author":"Jager","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0410","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/leu.2010.99","article-title":"Deletions of the transcription factor Ikaros in myeloproliferative neoplasms","volume":"24","author":"Jager","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0415","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0420","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.1073\/pnas.0601462103","article-title":"The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation","volume":"103","author":"Jamieson","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0425","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.1182\/blood-2009-02-205690","article-title":"Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic\/myeloproliferative neoplasms","volume":"113","author":"Jankowska","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0430","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/blood-2010-10-311019","article-title":"Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A","volume":"118","author":"Jankowska","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0435","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood-2005-05-1800","article-title":"JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia","volume":"106","author":"Jelinek","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0440","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1365-2141.2005.05719.x","article-title":"JAK2 V617F Mutation is uncommon in chronic myelomonocytic leukaemia","volume":"130","author":"Johan","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0445","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ng.334","article-title":"JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms","volume":"41","author":"Jones","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0450","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/sj.leu.2404513","article-title":"Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR\/ABL-negative myeloproliferative disorders","volume":"21","author":"Jost","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0455","doi-asserted-by":"crossref","first-page":"108","DOI":"10.4331\/wjbc.v2.i6.108","article-title":"Role of Ikaros in T-cell acute lymphoblastic leukemia","volume":"2","author":"Kastner","year":"2011","journal-title":"World J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0460","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2013.281","article-title":"Functional and cancer genomics of ASXL family members","volume":"109","author":"Katoh","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0465","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/ng.342","article-title":"A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms","volume":"41","author":"Kilpivaara","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0470","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1002\/cncr.22663","article-title":"Clinical correlates of JAK2V617F allele burden in essential thrombocythemia","volume":"109","author":"Kittur","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0475","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood-2011-01-331678","article-title":"Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression","volume":"118","author":"Klampfl","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0480","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0485","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1182\/blood-2009-04-215814","article-title":"TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)","volume":"114","author":"Kosmider","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0490","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0495","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2006-02-002030","article-title":"JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis","volume":"108","author":"Lacout","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0500","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/ajh.23138","article-title":"A novel mutation in MPL (Y252H) results in increased thrombopoietin sensitivity in essential thrombocythemia","volume":"87","author":"Lambert","year":"2012","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0505","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/ng.391","article-title":"Acquired mutations in TET2 are common in myelodysplastic syndromes","volume":"41","author":"Langemeijer","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0510","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1365-2141.2006.06348.x","article-title":"Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time","volume":"135","author":"Lasho","year":"2006","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0515","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMc1006966","article-title":"LNK mutations in JAK2 mutation-negative erythrocytosis","volume":"363","author":"Lasho","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0520","doi-asserted-by":"crossref","first-page":"e0035","DOI":"10.5041\/RMMJ.10169","article-title":"Calreticulin mutations in myeloproliferative neoplasms","volume":"5","author":"Lavi","year":"2014","journal-title":"Rambam Maimonides Med. J."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0525","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0530","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2005-05-1898","article-title":"The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia","volume":"106","author":"Levine","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0535","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","article-title":"DNMT3A mutations in acute myeloid leukemia","volume":"363","author":"Ley","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0540","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1016\/j.febslet.2007.06.072","article-title":"DNA architectural factor and proto-oncogene HMGA2 regulates key developmental genes in pluripotent human embryonic stem cells","volume":"581","author":"Li","year":"2007","journal-title":"FEBS Lett."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0545","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1242\/dmm.006817","article-title":"Mouse models of myeloproliferative neoplasms: JAK of all grades","volume":"4","author":"Li","year":"2011","journal-title":"Dis. Models Mech."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0550","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0952-7915(98)80165-9","article-title":"JAK\/STAT signaling by cytokine receptors","volume":"10","author":"Liu","year":"1998","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0555","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood-2009-01-198416","article-title":"Mutations in CBL occur frequently in juvenile myelomonocytic leukemia","volume":"114","author":"Loh","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0560","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.18632\/oncotarget.719","article-title":"p5 as a target in myeloproliferative neoplasms","volume":"3","author":"Lu","year":"2012","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0565","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0570","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/onc.2012.130","article-title":"The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies","volume":"32","author":"Luo","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0575","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1128\/MCB.17.3.1562","article-title":"Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways","volume":"17","author":"Luo","year":"1997","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0580","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.thromres.2009.02.004","article-title":"Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review","volume":"124","author":"Lussana","year":"2009","journal-title":"Thromb. Res."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0585","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1200\/JCO.2009.23.7503","article-title":"Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies","volume":"27","author":"Makishima","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0590","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/leu.2010.167","article-title":"Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies","volume":"24","author":"Makishima","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0595","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.3324\/haematol.12011","article-title":"JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis","volume":"92","author":"Martinez-Aviles","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0600","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00277-011-1330-0","article-title":"TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms","volume":"91","author":"Martinez-Aviles","year":"2012","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0605","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/bjh.12969","article-title":"JAK2 V617F and CALR mutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort","volume":"167","author":"McGaffin","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0610","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.leukres.2006.01.008","article-title":"JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia","volume":"30","author":"Mesa","year":"2006","journal-title":"Leukemia Res."},{"issue":"Pt 2","key":"10.1016\/j.critrevonc.2015.11.004_bib0615","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1042\/bj3440281","article-title":"Calreticulin one protein, one gene, many functions","volume":"344","author":"Michalak","year":"1999","journal-title":"Biochem. J."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0620","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1042\/BJ20081847","article-title":"Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum","volume":"417","author":"Michalak","year":"2009","journal-title":"Biochem. J."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0625","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1200\/JCO.2009.22.6985","article-title":"Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome","volume":"27","author":"Mohamedali","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0630","doi-asserted-by":"crossref","first-page":"11444","DOI":"10.1073\/pnas.0404241101","article-title":"Mpl Baltimore a thrombopoietin receptor polymorphism associated with thrombocytosis","volume":"101","author":"Moliterno","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0635","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1080\/10428190801947500","article-title":"Ikaros and acute leukemia","volume":"49","author":"Mullighan","year":"2008","journal-title":"Leukemia Lymphoma"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0640","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0645","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/ng.620","article-title":"Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes","volume":"42","author":"Nikoloski","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0650","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.exphem.2006.11.012","article-title":"Polycythemia vera is not initiated by JAK2V617F mutation","volume":"35","author":"Nussenzveig","year":"2007","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0655","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.4161\/cc.9.6.11034","article-title":"Gain-of-function c-CBL mutations associated with uniparental disomy of 11q in myeloid neoplasms","volume":"9","author":"Ogawa","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0660","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood-2010-02-270108","article-title":"Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms","volume":"116","author":"Oh","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0665","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0670","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2003-06-1845","article-title":"Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia","volume":"103","author":"Ozeki","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0675","doi-asserted-by":"crossref","first-page":"5","DOI":"10.6061\/clinics\/2013(01)OA02","article-title":"Evaluation of the association between the JAK2 46\/1 haplotype and chronic myeloproliferative neoplasms in a Brazilian population","volume":"68","author":"Pagliarini-e-Silva","year":"2013","journal-title":"Clinics"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0680","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2353\/jmoldx.2008.080015","article-title":"A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction","volume":"10","author":"Pancrazzi","year":"2008","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0685","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0690","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/sj.leu.2404810","article-title":"Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0695","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1182\/blood-2007-06-095703","article-title":"Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders","volume":"111","author":"Pardanani","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0700","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/leu.2010.77","article-title":"IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms","volume":"24","author":"Pardanani","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0705","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/leu.2010.163","article-title":"LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations","volume":"24","author":"Pardanani","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0710","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0715","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","article-title":"Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations","volume":"117","author":"Passamonti","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0720","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","article-title":"A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment","volume":"120","author":"Passamonti","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0725","doi-asserted-by":"crossref","first-page":"929840","DOI":"10.1155\/2013\/929840","article-title":"TET2 mutations in Ph-negative myeloproliferative neoplasms: identification of three novel mutations and relationship with clinical and laboratory findings","volume":"2013","author":"Patriarca","year":"2013","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0730","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/hmg\/ddq024","article-title":"The idic(X)(q13) in myeloid malignancies: breakpoint clustering in segmental duplications and association with TET2 mutations","volume":"19","author":"Paulsson","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0735","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3324\/haematol.11643","article-title":"The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels","volume":"92","author":"Percy","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0740","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/jcp.2009.065904","article-title":"JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia","volume":"62","author":"Pich","year":"2009","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0745","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1182\/blood-2007-07-101576","article-title":"Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders","volume":"111","author":"Pietra","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0750","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3324\/haematol.2010.034793","article-title":"Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms","volume":"96","author":"Pietra","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0755","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0760","doi-asserted-by":"crossref","first-page":"27266","DOI":"10.1074\/jbc.M111.258467","article-title":"Structural and functional relationships between the lectin and arm domains of calreticulin","volume":"286","author":"Pocanschi","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0765","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/BF00355839","article-title":"Two members of the JAK family of protein tyrosine kinases map to chromosomes 1p31.3 and 9p24","volume":"3","author":"Pritchard","year":"1992","journal-title":"Mamm. Genome"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0770","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12288-014-0385-1","article-title":"Coexistence of JAK2V617F mutation and BCR-ABL Translocation in a pregnant woman with essential thrombocythemia","volume":"30","author":"Qin","year":"2014","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0775","first-page":"2415","article-title":"JAK3: a novel JAK kinase associated with terminal differentiation of hematopoietic cells","volume":"9","author":"Rane","year":"1994","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0780","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ccr.2010.09.008","article-title":"Myeloid leukemia development in c-Cbl RING finger mutant mice is dependent on FLT3 signaling","volume":"18","author":"Rathinam","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0785","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/ajh.22216","article-title":"TP53 mutations and polymorphisms in primary myelofibrosis","volume":"87","author":"Raza","year":"2012","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0790","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1182\/blood-2005-06-2596","article-title":"Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML","volume":"107","author":"Reindl","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0795","first-page":"719","article-title":"Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic\/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis","volume":"91","author":"Remacha","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0800","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1038\/sj.leu.2404405","article-title":"High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis","volume":"20","author":"Renneville","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0805","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1006\/geno.1996.0520","article-title":"Genomic sequence, organization, and chromosomal localization of human JAK3","volume":"37","author":"Riedy","year":"1996","journal-title":"Genomics"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0810","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0815","doi-asserted-by":"crossref","first-page":"pe 1","DOI":"10.1126\/stke.2001.85.pe1","article-title":"Lnk adaptor: novel negative regulator of B cell lymphopoiesis","volume":"2001","author":"Rudd","year":"2001","journal-title":"Sci. STKE"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0820","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1182\/blood-2014-01-550434","article-title":"CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0825","doi-asserted-by":"crossref","first-page":"47954","DOI":"10.1074\/jbc.M205156200","article-title":"The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction","volume":"277","author":"Saharinen","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0830","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2009-01-197525","article-title":"Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms","volume":"114","author":"Saint-Martin","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0835","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature08240","article-title":"Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms","volume":"460","author":"Sanada","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0840","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1182\/blood-2014-07-587238","article-title":"The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm","volume":"124","author":"Sangkhae","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0845","first-page":"1040","article-title":"The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases","volume":"23","author":"Sattler","year":"1995","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0850","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2009-09-245381","article-title":"Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms","volume":"115","author":"Schaub","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0855","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3324\/haematol.13224","article-title":"Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis","volume":"94","author":"Schnittger","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0860","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.3324\/haematol.2012.065375","article-title":"Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative disorders: an analysis of 636 cases","volume":"97","author":"Schnittger","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0865","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0870","doi-asserted-by":"crossref","first-page":"820","DOI":"10.3109\/10428194.2014.939963","article-title":"CALR and ASXL1 mutation analysis in 190 patients with essential thrombocythemia","volume":"56","author":"Shen","year":"2015","journal-title":"Leukemia Lymphoma"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0875","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1038\/leu.2012.94","article-title":"TET2 is essential for survival and hematopoietic stem cell homeostasis","volume":"26","author":"Shide","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0880","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/cncr.20440","article-title":"Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome","volume":"101","author":"Shih","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0885","article-title":"JAK2, CALR, and MPL mutation spectrum in Japanese myeloproliferative neoplasms patients","author":"Shirane","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0890","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.mrfmmm.2008.07.010","article-title":"Roles of the EZH2 histone methyltransferase in cancer epigenetics","volume":"647","author":"Simon","year":"2008","journal-title":"Mutat. Res."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0895","series-title":"Hematology\/the Education Program of the American Society of Hematology","first-page":"178","article-title":"FLT3 mutations: biology and treatment","author":"Small","year":"2006"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0900","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/MOH.0b013e32835d82fe","article-title":"Polycythemia vera and essential thrombocythemia: new developments in biology with therapeutic implications","volume":"20","author":"Soriano","year":"2013","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0905","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1182\/blood-2005-06-2600","article-title":"An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor","volume":"107","author":"Staerk","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0910","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2005-03-1183","article-title":"The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both atypical myeloproliferative disorders and myelodysplastic syndromes","volume":"106","author":"Steensma","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0915","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/sj.leu.2404206","article-title":"JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained","volume":"20","author":"Steensma","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0920","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2404418","article-title":"t(3;12)(q26;q14) in polycythemia vera is associated with upregulation of the HMGA2 gene","volume":"20","author":"Storlazzi","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0925","first-page":"1","article-title":"Calreticulin gene mutations in myeloproliferative neoplasms without Janus kinase 2 mutations","author":"Sun","year":"2014","journal-title":"Leukemia Lymphoma"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0930","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/jcp.20694","article-title":"The Cbl family proteins: ring leaders in regulation of cell signaling","volume":"209","author":"Swaminathan","year":"2006","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0935","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3324\/haematol.2010.029678","article-title":"Extent of hematopoietic involvement by TET2 mutations in JAK2V(6)(1)(7)F polycythemia vera","volume":"96","author":"Swierczek","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0940","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood-2006-02-005751","article-title":"Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation","volume":"108","author":"Szpurka","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0945","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1126\/science.1170116","article-title":"Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1","volume":"324","author":"Tahiliani","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0950","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1084\/jem.20011170","article-title":"Enhanced hematopoiesis by hematopoietic progenitor cells lacking intracellular adaptor protein, Lnk","volume":"195","author":"Takaki","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0955","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1182\/blood.V93.1.125","article-title":"Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L","volume":"93","author":"Taksin","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0960","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","article-title":"Myeloproliferative neoplasms\u2014a contemporary review","volume":"1","author":"Tefferi","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0965","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0970","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1002\/cncr.24440","article-title":"The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos","volume":"115","author":"Tefferi","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0975","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/leu.2009.37","article-title":"Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0980","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2009.47","article-title":"TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0985","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/leu.2009.59","article-title":"Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS\/MPN and AML","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0990","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2014.57","article-title":"CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib0995","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1038\/leu.2014.148","article-title":"Calreticulin mutations and long-term survival in essential thrombocythemia","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1000","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/leu.2014.83","article-title":"Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1005","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1010","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/leu.2014.35","article-title":"An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1015","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood-2014-07-588426","article-title":"The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1020","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1025","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1182\/blood-2010-11-315614","article-title":"How I treat myelofibrosis","volume":"117","author":"Tefferi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1030","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/ijc.23694","article-title":"Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases","volume":"123","author":"Teofili","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1035","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3324\/haematol.2009.007542","article-title":"Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis","volume":"95","author":"Teofili","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1040","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s11899-013-0184-z","article-title":"Genetic basis of MPN: beyond JAK2-V617F","volume":"8","author":"Them","year":"2013","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1045","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood-2006-12-062125","article-title":"Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation","volume":"110","author":"Theocharides","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1050","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1084\/jem.20040762","article-title":"Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis","volume":"200","author":"Tong","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1055","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jhep.2014.08.032","article-title":"Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis","volume":"62","author":"Turon","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1060","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2011-02-292102","article-title":"New mutations and pathogenesis of myeloproliferative neoplasms","volume":"118","author":"Vainchenker","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1065","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1070","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1182\/blood-2008-01-135897","article-title":"Characteristics and clinical correlates of MPL 515W>L\/K mutation in essential thrombocythemia","volume":"112","author":"Vannucchi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1075","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1080","series-title":"Hematology\/the Education Program of the American Society of Hematology","first-page":"222","article-title":"Management of myelofibrosis","author":"Vannucchi","year":"2011"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1085","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1084\/jem.20011883","article-title":"Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice","volume":"195","author":"Velazquez","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1090","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1038\/sj.leu.2404379","article-title":"JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?","volume":"20","author":"Verstovsek","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1095","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/sj.leu.2404086","article-title":"JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients","volume":"20","author":"Vizmanos","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1100","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/leu.2011.44","article-title":"Recurrent DNMT3A mutations in patients with myelodysplastic syndromes","volume":"25","author":"Walter","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1105","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/sj.leu.2404316","article-title":"Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features","volume":"20","author":"Wang","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1110","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.biocel.2012.02.009","article-title":"Calreticulin signaling in health and disease","volume":"44","author":"Wang","year":"2012","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1115","doi-asserted-by":"crossref","first-page":"485645","DOI":"10.1155\/2014\/485645","article-title":"Mutation analysis of JAK2V617F, FLT3-ITD, NPM1, and DNMT3A in Chinese patients with myeloproliferative neoplasms","volume":"2014","author":"Wang","year":"2014","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1120","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1182\/blood-2005-12-4824","article-title":"Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model","volume":"107","author":"Wernig","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1125","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.exphem.2007.08.010","article-title":"Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis","volume":"35","author":"Williams","year":"2007","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1130","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/PDM.0b013e31828564fe","article-title":"FLT3 mutations in myeloproliferative neoplasms: the Beaumont experience","volume":"22","author":"Williams","year":"2013","journal-title":"Diagn. Mol. Pathol."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1135","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11670-012-0072-4","article-title":"JAK2 V617F, MPL W515L and JAK2 exon 12 mutations in chinese patients with primary myelofibrosis","volume":"24","author":"Xia","year":"2012","journal-title":"Chin. J. Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1140","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1038\/onc.2010.117","article-title":"Array-based genomic resequencing of human leukemia","volume":"29","author":"Yamashita","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1145","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/ng.788","article-title":"Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia","volume":"43","author":"Yan","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1150","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1101\/gad.1554707","article-title":"Oncogenic HMGA2: short or small?","volume":"21","author":"Young","year":"2007","journal-title":"Genes Dev."},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1155","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1182\/blood-2011-11-390252","article-title":"Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome","volume":"119","author":"Zhang","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.11.004_bib1160","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/jcmm.12103","article-title":"Methylation profiling of SOCS1, SOCS2, SOCS3, CISH and SHP1 in Philadelphia-negative myeloproliferative neoplasm","volume":"17","author":"Zhang","year":"2013","journal-title":"J. Cell. Mol. Med."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842815300743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842815300743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T12:50:37Z","timestamp":1653655837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842815300743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":232,"alternative-id":["S1040842815300743"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2015.11.004","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myeloproliferative neoplasms: Current molecular biology and genetics","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2015.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}